More so than established contract manufacturing organizations and nonclinical contract research organizations in Europe and
North America, up-and-coming contract service providers born in India and China have embraced the global nature of drug development.
These companies were originally established to exploit the big differentials in wages paid to chemists and other scientists
in their home countries versus North America and Europe. However, the most strategically committed CROs have realized that
in addition to offering a platform for low-cost drug development, they need to be near their customers to secure those relationships.
Proximity increases opportunities for relationship building, which leads to trust and more business. Further, there are certain
activities such as projects that require close interaction with client scientists and/or involve intellectual property protection
issues that are best carried out when close to the client's research and development (R&D) operations.
In the past two years, several India-based contractors have stepped up to acquire European and North American bases of operations,
sometimes paying a considerable premium for the privilege. These include companies such as Nicholas Piramal (Mumbai), which
bought operations from Avecia and Pfizer in the United Kingdom; Dishman Pharmaceuticals and Chemicals (Ahmedabad), which bought
Carbogen and Amcis in Switzerland; and Jubilant Organosys (Noida), which acquired injectables manufacturer Hollister-Stier
Laboratories in the US.
Those companies are about to be joined by Shanghai-based WuXi PharmaTech, which announced plans in late December to acquire
AppTec Laboratory Services, Inc. (St. Paul, MN) for $162.7 million. AppTec, which has 495 employees, provides manufacturing
and laboratory services to the biopharmaceutical and medical device industries. The company also provides clinical-scale cell
culture manufacturing at its Philadelphia facility, where it has a 2500 L bioreactor train and a number of Wave bioreactors.
AppTec's growth has been nothing short of phenomenal. Revenues for 2007 of $71 million were up 40% from $51 million in 2006
and more than three times 2004 revenues of $23 million. Most of that growth has been organic and has come from the biopharmaceutical
WuXi's story has been striking as well, as it has emerged as a major player in chemistry-based discovery, process development,
and manufacturing services since 2002. Its 2007 revenues of $133 million were double its 2006 revenues and almost eight times
its 2004 revenues of $21 million. In 2007, WuXi successfully completed an initial public offering (IPO) on the New York Stock
Exchange, raising $155 million. It has 2700 employees, including 2100 scientists and claims most major pharmaceutical companies
Aside from AppTec's growth prospects, WuXi CEO Ge Li cited three elements in his strategic rationale for the AppTec acquisition:
WuXi gets biologics capabilities and expertise to complement its chemistry position; it expands its US customer base and addressable
market; and it gains an operational footprint in the US. Li added that the company plans to "amplify" AppTec's capabilities
in China rather than replicate them; we take this to mean building larger scale biomanufacturing capabilities.
Building very large-scale facilities has been a key part of WuXi's strategy. Its facilities include a 630,000-ft2 discovery chemistry laboratory, a 220,000-ft2 process development and manufacturing facility in Shanghai, and a 130,000-ft2 chemical manufacturing facility in Tianjin. It is building a 267,000-ft2 preclinical toxicology facility in Suzhou, China, a bold move to expand its service offerings beyond chemistry and leap ahead
of preclinical market leaders Covance (Princeton, NJ) and Charles River Laboratories (Wilmington, MA) in terms of China-based
The aggressive moves by WuXi PharmaTech, Jubilant Organosys, Nicholas Piramal, and other Asian pharmaceutical services providers
stand out in contrast to Western competitors who have been in the business much longer and would seem to have more resources
and stronger pharmaceutical company relationships to draw on. Thus far, only a few Western companies, notably Albany Molecular
Research, Aptuit (Greenwich, CT), and Lonza (Basel, Switzerland), have taken the plunge to set up wholly owned chemistry and
development operations in Asia.